COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC (POLICE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01740804
Recruitment Status : Completed
First Posted : December 4, 2012
Last Update Posted : December 5, 2016
Information provided by (Responsible Party):
Guangdong Association of Clinical Trials

Brief Summary:

Primary endpoint To observe the dynamic changes of CTC during the process of platinum based chemotherapy in advanced NSCLC.

To study the relationship between CTC count and clinical outcome of chemotherapy (ORR and PFS).

Secondary endpoint To study the relationship between CTC and overall survival. To study the molecular feature of CTC, such as epidermal growth factor receptor (EGFR), KRAS, CD117, etc.

Condition or disease
Carcinoma, Non-Small-Cell Lung Cell, Circulating Tumor

Detailed Description:
This is a prospective observational non-intervention study evaluating the dynamic CTC count during the chemotherapy. Patients provide written informed consent and pass the screening. Peripheral blood will be drawn before and after the first line chemotherapy. Analyze the relationship between CTC count and clinical outcome. The time points of blood drawing are set as following: once prior to 1st cycle of chemotherapy, once 1 week prior to 2nd cycle of chemotherapy, posterior to 4th cycle (or less than 4th cycle) of chemotherapy and once when progressive disease (PD). The specific blood tube CellSave Tube will be used, 7.5ml blood sample every time. One follow-up (including by phone) be made every 3 month after PD until death. The clinical outcome of first line chemotherapy will be ultimately obtained.

Layout table for study information
Study Type : Observational
Actual Enrollment : 180 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective Observational Study on the Dynamic Changes of CTC Enumeration in Advanced NSCLC With 1st Line Chemotherapy
Study Start Date : November 2012
Actual Primary Completion Date : April 2016
Actual Study Completion Date : June 2016

Primary Outcome Measures :
  1. dynamic CTC changes during chemotherapy [ Time Frame: baseline, 3 weeks and up to progression disease of chemotherapy ]

Biospecimen Retention:   Samples With DNA
The DNA sample will be rtetained for molecular analysis such as EGFR, KRAS, etc.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Advanced NSCLC (stage IIIb/IV or recurrent NSCLC)

Inclusion Criteria:

  • Patients with histologically documented, locally advanced or recurrent (stage IIIb and not amenable or combined modality treatment) or metastatic (stage IV) non-small cell lung cancer.
  • ECOG performance status of ≤ 2.
  • Patients without prior chemotherapy or therapy with systemic anti-neoplastic therapy. Previous adjuvant or neo-adjuvant treatment or combine chemoradiotherapy for stage I to III is permitted if completed > 12 months before enrollment.
  • According to routine first line doublet chemotherapy in clinical practice, Cisplatin or carboplatin combined with gemcitabine or paclitaxel or docetaxol or Vinorelbine were recommended.
  • Patients must have measurable disease according to the RECIST (version 1.1) criteria.
  • Life expectancy of at least 12 weeks.
  • Age ≥ 18 years.
  • Written (signed) informed Consent to participate in the study.
  • Adequate organ function as defined by the following criteria:Liver function: SGOT (AST) and SGPT (ALT) ≤ 2.5 X ULN in the absence of liver metastases or up to 5 X ULN in case of liver metastases. Total bilirubin ≤ 1.5ULN.Bone marrow function: Granulocyte count ≥ 1,500/mm3 and platelet count ≥100,000/mm3 and hemoglobin ≥90g/dl. Renal function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 ml/min. (based on modified Cockcroft-Gault formula).
  • For all females of childbearing potential a negative serum/urine pregnancy test must be obtained within 48 hours before enrollment. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential.

Exclusion Criteria:

  • Patients with prior chemotherapy or therapy with systemic anti-cancer therapy including target therapy. Previous adjuvant or neo-adjuvant treatment for non-metastatic disease is permitted if completed ≥ 6 months before the enrollments.
  • Patients with history of any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
  • Patients who have brain metastasis or spinal cord compression. It is permitted if the patient has been treated with surgery and/or radiation with evidence of stable disease for at least 4 weeks.
  • Patients who are at risk (in the investigator's opinion) of transmitting human immunodeficiency virus (HIV) through blood or other body fluids.
  • Nursing or lactating women.
  • Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
  • Unwilling to write informed consent to participate in the study.
  • Patients who is unwilling to accept the follow-up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01740804

Layout table for location information
China, Guangdong
Guangdong general hospital
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
Guangdong Association of Clinical Trials
Layout table for investigator information
Principal Investigator: Yi-Long Wu, MD Guangdong General Hospital & Guangdong Academy of Medical Sciences
Layout table for additonal information
Responsible Party: Guangdong Association of Clinical Trials Identifier: NCT01740804    
Other Study ID Numbers: CTONG1202
First Posted: December 4, 2012    Key Record Dates
Last Update Posted: December 5, 2016
Last Verified: September 2015
Keywords provided by Guangdong Association of Clinical Trials:
Circulating tumor cell
Non-small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Neoplastic Cells, Circulating
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes